BlackRock Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

BlackRock Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.15M	Buy	96,028 +593	+0.6%	+$11.6K	﹤0.01%	1475
2016 Q3	$2.17M	Buy	95,435 +8,321	+10%	+$195K	﹤0.01%	1435
2016 Q2	$2.06M	Sell	87,114 -35,837	-29%	-$885K	﹤0.01%	1412
2016 Q1	$2.51M	Buy	122,951 +58,617	+91%	+$1.86M	﹤0.01%	1325
2015 Q4	$3.31M	Sell	64,334 -3,611	-5%	-$175K	﹤0.01%	1236
2015 Q3	$2.9M	Buy	67,945 +4,676	+7%	+$226K	﹤0.01%	1253
2015 Q2	$2.88M	Buy	63,269 +23,146	+58%	+$931K	﹤0.01%	1141
2015 Q1	$1.52M	Buy	40,123 +18,054	+82%	+$620K	﹤0.01%	1335
2014 Q4	$625K	Buy	22,069 +2,160	+11%	+$60K	﹤0.01%	1828
2014 Q3	$503K	Sell	19,909 -3,849	-16%	-$101K	﹤0.01%	1973
2014 Q2	$693K	Sell	23,758 -76,853	-76%	-$1.86M	﹤0.01%	1773
2014 Q1	$2.61M	Buy	100,611 +28,049	+39%	+$749K	﹤0.01%	1113
2013 Q4	$1.87M	Buy	72,562 +42,074	+138%	+$1.02M	﹤0.01%	1211
2013 Q3	$816K	Buy	30,488 +25,852	+558%	+$615K	﹤0.01%	1549
2013 Q2	$114K	Buy	+4,636	New	+$92.1K	﹤0.01%	2815

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Advisors's PTLA Position: Q4 2016 in Review

BlackRock Advisors increased its Portola Pharmaceuticals, Inc. (PTLA) stake by 0.62% in Q4 2016, buying an estimated $11.6K and bringing the position to 96,028 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1475.

BlackRock Advisors first reported a position in PTLA in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.31M in Q4 2015. 150 funds tracked by Wall St. Rank hold PTLA as of Q4 2016.

BlackRock Advisors held 96,028 shares of Portola Pharmaceuticals, Inc. worth $2.15M as of Q4 2016.
BlackRock Advisors bought 593 Portola Pharmaceuticals, Inc. shares in Q4 2016, an estimated $11.6K.
Portola Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1475 holding.
BlackRock Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Portola Pharmaceuticals, Inc. position peaked at $3.31M in Q4 2015.
150 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.